Solubility based Biowaiver [Dissolution / BCS / IVIVC]

posted by Amalia – Greece, 2018-10-02 08:35 (934 d 03:00 ago) – Posting: # 19362
Views: 4,482

» Where is the difference coming from?

None of the excipients are proportional.

» Is the API less than 5% of the total weight of the tablet?

The API of the lowest strength is less than 5%. But not of the highest strength for which a BE study was performed.

» Take a look at the General biowaiver criteria on page 12 of the guideline. If you don't meet the conditions stated in c), you'll need to conduct a BE study at the lower strength too.

I Know. The most probable scenario is that we will perform a BE study. We are just trying to see if a justification can be made.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! Please follow the Forum’s Policy[Helmut]

Complete thread:

Activity
 Admin contact
21,429 posts in 4,479 threads, 1,512 registered users;
online 24 (0 registered, 24 guests [including 4 identified bots]).
Forum time: Friday 11:36 UTC (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5